Clinical Trial Update: Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating omega-3 fatty acids to prevent atrial fibrillation after coronary artery bypass grafting was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Ischemic Heart Disease

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Meshalkin Research Institute of Pathology of Circulation | Conditions: Ischemic Heart Disease, Atrial Fibrillation | Phase 3 | Status: TERMINATED